Phase I Study of Tipifarnib (R115777) and Sorafenib (BAY 43-9006) in Patients With Biopsiable Advanced Cancers
Phase of Trial: Phase I
Latest Information Update: 02 May 2017
At a glance
- Drugs Sorafenib (Primary) ; Tipifarnib (Primary)
- Indications Cancer
- Focus Adverse reactions
- 26 Apr 2017 Status changed from active, no longer recruiting to completed.
- 14 Jun 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Mar 2017.
- 25 Feb 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov